Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Multiple Sclerosis

• Publication date

  2012-07-23

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1177/1352458512454774PMID 22824644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The California verbal learning test

  2016cited by this paper
• Executive Function Performance Test

  2014cited by this paper
• Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

  2012cited by this paper
• Cognition in multiple sclerosis.

  2011cited by this paper
• L-amphetamine improves memory in MS patients with objective memory impairment

  2011cited by this paper
• Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

  2011cited by this paper
• The Relationship between Neurocognitive Behavior of Executive Functions and the EFPT in Individuals with Multiple Sclerosis

  2011cited by this paper
• Risk factors for and management of cognitive dysfunction in multiple sclerosis

  2011cited by this paper
• Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

  2011cited by this paper
• Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

  2010cited by this paper
• Actual reality: a new approach to functional assessment in persons with multiple sclerosis.

  2010cited by this paper
• Outcome measurement in multiple sclerosis: detection of clinically relevant improvement

  2010cited by this paper
• Validation of the Multiple Sclerosis Neuropsychological Screening Questionnaire in Argentina

  2009cited by this paper
• The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial

  2009cited by this paper
• The relationship between cognitive deficits and everyday functional activities in multiple sclerosis.

  2008cited by this paper
• Cognitive impairment in multiple sclerosis.

  2008cited by this paper
• Relationship of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) to functional, emotional, and neuropsychological outcomes.

  2007cited by this paper
• The relationship between neuropsychological measures and the Timed Instrumental Activities of Daily Living task in multiple sclerosis

  2007cited by this paper
• The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis

  2007cited by this paper
• Donepezil Improved Memory in Multiple Sclerosis in a Randomized Clinical Trial

  2006cited by this paper
• Predicting neuropsychological abnormalities in multiple sclerosis.

  2006cited by this paper
• Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)

  2006cited by this paper
• Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

  2006cited by this paper
• Perceived cognitive dysfunction and observed neuropsychological performance: Longitudinal relation in persons with multiple sclerosis

  2005cited by this paper
• Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis

  2005cited by this paper
• Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.

  2005cited by this paper
• Interpreting patient/informant discrepancies of reported cognitive symptoms in MS

  2005cited by this paper
• Reliable screening for neuropsychological impairment in multiple sclerosis

  2004cited by this paper
• Treatment of pseudobulbar affect in ALS: October 26 Highlight and Commentary

  2004cited by this paper
• The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C omposite

  2004cited by this paper
• Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire

  2003cited by this paper
• Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach

  2002cited by this paper
• Quantitative functional measures in MS: What is a reliable change?

  2002cited by this paper
• Timed Instrumental Activities of Daily Living Tasks: Relationship to Cognitive Function and Everyday Performance Assessments in Older Adults

  2002cited by this paper
• The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite

  2000cited by this paper
• Detecting significant change in neuropsychological test performance: A comparison of four models

  1999cited by this paper
• The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis

  1999cited by this paper
• Statistical Methods For Assessing Measurement Error (Reliability) in Variables Relevant to Sports Medicine

  1998cited by this paper
• The measurement of ambulatory impairment in multiple sclerosis

  1997cited by this paper
• Evaluation of instrument error and method agreement.

  1996cited by this paper
• Guidelines for neuropsychological research in multiple sclerosis.

  1990cited by this paper
• Measurement of health status. Ascertaining the minimal clinically important difference.

  1989cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• Adult Norms for the Nine Hole Peg Test of Finger Dexterity

  1985cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• expanded disability status scale (EDSS) Rating neurologic impairment in multiple sclerosis: An

  1983cited by this paper
• AKUFO AND IBARAPA.

  1965cited by this paper

• Lowered ratio of corticospinal excitation to inhibition predicts greater disability, poorer motor and cognitive function in multiple sclerosis

  2024cites this paper
• Do baseline cognitive status, participant specific characteristics and EDSS impact changes of cognitive performance following aerobic exercise intervention in multiple sclerosis?

  2021cites this paper
• Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology

  2021cites this paper
• Cognitive functioning in everyday life: The development of a questionnaire on instrumental activities of daily living in multiple sclerosis

  2021cites this paper
• Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice

  2020cites this paper
• The Contribution of Perceived Memory and Information Processing Deficits on Multiple Sclerosis Cognitive Difficulties

  2020cites this paper
• Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses

  2020cites this paper
• The incremental value of neuropsychological assessment: A critical review

  2020cites this paper
• Multiple sclerosis: clinical trial design 2019

  2019cites this paper
• Effect of dalfampridine on information processing speed impairment in multiple sclerosis

  2019cites this paper
• Cognitive impairment as one of the important non‐motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders

  2019cites this paper
• Cognition in multiple sclerosis

  2018cites this paper
• Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

  2017cites this paper
• Kognitive Störungen bei Multipler Sklerose und anderen autoimmunen Erkrankungen des zentralen Nervensystems // Cognitive dysfunction in multiple sclerosis and other autoimmune disorders in central nervous system

  2017cites this paper
• Clinical trial design for progressive MS trials

  2017cites this paper
• Processing speed test: Validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting

  2017cites this paper
• Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis

  2016cites this paper
• Benchmarks of meaningful impairment on the MSFC and BICAMS

  2016cites this paper
• Therapeutic Advances in Neurological Disorders

  2016cites this paper
• Secondary Progressive Multiple Sclerosis: Definition and Measurement

  2016cites this paper
• Utility of the INECO frontal screening (IFS) in the detection of executive dysfunction in patients with relapsing-remitting multiple sclerosis (RRMS)

  2015cites this paper
• La part de l’inflammation dans la pathogénie de la sclérose en plaques

  2015cites this paper
• Assessing cognition in MS clinical trials: The Cognitive Assessment Interview (CAI) (P3.233)

  2015cites this paper
• The acute effects of varying intensities of treadmill walking exercise on cognition in persons with multiple sclerosis

  2015cites this paper
• Perceived Cognitive Difficulties and Cognitive Test Performance as Predictors of Employment Outcomes in People with Multiple Sclerosis

  2015cites this paper
• Are cognitive interventions for Multiple Sclerosis effective and feasible?

  2014cites this paper
• Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis

  2014cites this paper
• Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan

  2014cites this paper
• Negative work events and accommodations in employed multiple sclerosis patients

  2014cites this paper
• Corrélats structuraux et fonctionnels de l'atteinte cognitive précoce au cours de la sclérose en plaques

  2014cites this paper
• Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

  2013cites this paper
• Executive functioning in Asian pathological gamblers

  2013cites this paper